Rational drug discovery relies on pathognomonic molecular reporters of disease or biomarkers. Therefore biomarkers contain relational or contextual information about disease pathophysiology. Two broad pathways can be taken to identify. biomarkers: a 'top-down', holistic approach that makes no assumptions about biomarker type, or the 'bottom-up' approach, which is hypothesis driven and relies on a priori information. Both approaches involve parallel or sequential methods that include genomic and proteomic profiling. Biomarker discovery and translational medicine owe much to isotopic techniques because these provide near-real-time information about disease status as diagnostics, in drug delivery and for monitoring treatment. Here, we provide an overview of recent developments and some insight into the future role of isotopes in biomarker discovery and disease therapy.
Isotopic biomarker discovery and application in translational medicine / Bayele, Hk; Chiti, A; Colina, R; Fernandes, O; Khan, B; Krishnamoorthy, R; Ozdag, H; Padua, Ra. - In: DRUG DISCOVERY TODAY. - ISSN 1359-6446. - 15:3-4(2010), pp. 127-136. [10.1016/j.drudis.2009.12.005]